NRL-1

DRUG2 trials

Sponsors

Neurelis, Inc.

Conditions

Acute Repetitive SeizuresBreakthrough Seizures

Phase 1

Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects

CompletedNCT02724423

Neurelis, Inc.Acute Repetitive Seizures

Start: 2016-06-30End: 2019-09-10Updated: 2021-10-05

Phase 3

Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

CompletedNCT02721069

Neurelis, Inc.Acute Repetitive Seizures, Breakthrough Seizures

Start: 2016-04-11End: 2020-07-23Updated: 2022-01-31

Related Papers

Systematic statistical analysis of change in SEIzure interVAL with diazepam nasal spray supports this novel clinical endpoint for immediate-use seizure medication.

2026-04-01

Safety and effectiveness of diazepam nasal spray in patients with Rett syndrome and seizure clusters: post hoc analyses from a long-term safety study and survey of severity and burden

Frontiers in Neurology2026-02-23

Rapid Rescue Treatment with Diazepam Nasal Spray Leads to Faster Seizure Cluster Termination in Epilepsy: An Exploratory Post Hoc Cohort Analysis.

2024-01-046 citations

Safety of Diazepam Nasal Spray in Pediatric Patients With Developmental Epileptic Encephalopathies: Results From a Long-term Phase 3 Safety Study

Journal of Child Neurology2023-05-014 citations

Quality-of-life results in adults with epilepsy using diazepam nasal spray for seizure clusters from a long-term, open-label safety study.

2022-07-0812 citations

Final results from a Phase 3, long‐term, open‐label, repeat‐dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy

Epilepsia2021-08-2164 citations

Examining the patient and caregiver experience with diazepam nasal spray for seizure clusters: Results from an exit survey of a phase 3, open-label, repeat-dose safety study.

2021-05-1932 citations